These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 16286482)

  • 21. [Detection of the first strain of glycopeptide intermediary Staphylococcus aureus in Tunis Rabta hospital].
    Zribi M; Etienne J; El Euch D; Zribi H; Bes M; Meugnier H; Masmoudi A; Osman AB; Fendri C
    Pathol Biol (Paris); 2011 Dec; 59(6):334-5. PubMed ID: 19942369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
    Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
    Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Endemic heteroresistant glycopeptide intermediate Staphylcoccus aureus (hGISA) comprising unrelated clonal types and not associated with vancomycin therapy].
    Lecaillon E; Gueudet P; Wooton M; Walsh TR; Macgowan AP; Jones ME
    Pathol Biol (Paris); 2002 Nov; 50(9):525-9. PubMed ID: 12490414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multilocus sequence typing (MLST) shows that the 'Iberian' clone of methicillin-resistant Staphylococcus aureus has spread to France and acquired reduced susceptibility to teicoplanin.
    Heym B; Le Moal M; Armand-Lefevre L; Nicolas-Chanoine MH
    J Antimicrob Chemother; 2002 Sep; 50(3):323-9. PubMed ID: 12205056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.
    Sancak B; Ercis S; Menemenlioglu D; Colakoglu S; Hasçelik G
    J Antimicrob Chemother; 2005 Sep; 56(3):519-23. PubMed ID: 16046461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains.
    Wootton M; Bennett PM; MacGowan AP; Walsh TR
    J Antimicrob Chemother; 2005 Nov; 56(5):944-7. PubMed ID: 16157619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals.
    Hubert SK; Mohammed JM; Fridkin SK; Gaynes RP; McGowan JE; Tenover FC
    J Clin Microbiol; 1999 Nov; 37(11):3590-3. PubMed ID: 10523558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides.
    El Solh N; Davi M; Morvan A; Damon HA; Marty N;
    J Antimicrob Chemother; 2003 Oct; 52(4):691-4. PubMed ID: 12951351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antibiotics resistance of meticilline-resistant Staphylococcus aureus: detection of the first glycopeptides low sensibility strains in Tunisia].
    Mastouri M; Nour M; Ben Nejma M; Bouallegue O; Hammami M; Khedher M
    Pathol Biol (Paris); 2006 Feb; 54(1):33-6. PubMed ID: 16376176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of glycopeptide hetero-intermediate Staphylococcus aureus strains in Maltese hospitals.
    Borg MA; Zerafa R; Morrison D; Cuschieri P
    Clin Microbiol Infect; 2005 May; 11(5):405-7. PubMed ID: 15819869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolutionary relationships between sporadic and epidemic strains of healthcare-associated methicillin-resistant Staphylococcus aureus.
    Hallin M; Denis O; Deplano A; De Ryck R; Crèvecoeur S; Rottiers S; de Mendonça R; Struelens MJ
    Clin Microbiol Infect; 2008 Jul; 14(7):659-69. PubMed ID: 18558938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antibiotic susceptibility of Staphylococcus aureus strains isolated in two university hospitals in Rabat, Morocco].
    Elhamzaoui S; Benouda A; Allali F; Abouqual R; Elouennass M
    Med Mal Infect; 2009 Dec; 39(12):891-5. PubMed ID: 19269758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new microbiological problem in intensive care units: environmental contamination by MRSA with reduced susceptibility to glycopeptides.
    Perdelli F; Dallera M; Cristina ML; Sartini M; Ottria G; Spagnolo AM; Orlando P
    Int J Hyg Environ Health; 2008 Mar; 211(1-2):213-8. PubMed ID: 17652023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis.
    Majcherczyk PA; Barblan JL; Moreillon P; Entenza JM
    Microb Pathog; 2008; 45(5-6):408-14. PubMed ID: 18930804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial resistance of community and hospital acquired Staphylococcus aureus isolates to oxacillin and glycopeptides.
    Anwar MS; Bokhari SR
    J Coll Physicians Surg Pak; 2003 Jan; 13(1):33-6. PubMed ID: 12685973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Hsu DI; Hidayat LK; Quist R; Hindler J; Karlsson A; Yusof A; Wong-Beringer A
    Int J Antimicrob Agents; 2008 Nov; 32(5):378-85. PubMed ID: 18701261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999].
    Nashev D; Toshkova K; Gavrilova V
    Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prospective study of Staphylococcus aureus with reduced susceptibility to glycopeptides].
    Cantón R; Mir N; Martínez-Ferrer M; Sánchez del Saz B; Soler I; Baquero F
    Rev Esp Quimioter; 1999 Mar; 12(1):48-53. PubMed ID: 10896469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.